First-line cytoreductive treatment in MNPs

Dr Chris Hillis is an assistant professor in the Division of Oncology at McMaster University and hematologist at the Juravinski Hospital and Cancer Centre.

0:00

Loaded: 0%

Progress: 0%

Stream TypeLIVE

0:00

Which cytoreductive drug is your first-line option for the treatment of myeloproliferative neoplasms (MNPs)?

Chris Hillis, MD, MSc: Hydroxyurea or hydroxycarbamide remain the first-line cytoreductive therapies in MPNs in 2019. In young patients and in patients who wish to become pregnant who do require cytoreductive therapy we would use interferon as first-line [treatment].

See also

Tests to establish the cause of secondary polycythemia What tests are useful in establishing the cause of secondary polycythemia?
Management of patients with a low burden of JAK2 mutation and a history of thrombosis What is your approach in a patient with a low burden of JAK2 mutation without other diagnostic criteria for myeloproliferative neoplasms (MPNs)? Does this approach change if the patient has a history of thrombosis?
Genetic testing in the setting of high ferritin to exclude hemochromatosis Does a negative genetic test (C282Y and H63D) result exclude hemochromatosis in a patient with transferrin saturation >45% and ferritin level >1000?
Myeloproliferative neoplasms: Tasks for internists A lecture by Dr Chris Hillis, from McMaster University, Canada, delivered at McMaster International Review Course in Internal Medicine (MIRCIM) in May 2019.
Screening tests in patients with a suspected bleeding disorder What tests do you perform in a patient with a suspected bleeding disorder who has normal coagulation screening test results (platelet count, prothrombin time, partial thromboplastin time, thrombin time, fibrinogen)?

First-line cytoreductive treatment in MNPs

Social Media